Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Yidafan (ivonescimab)
i
Other names:
AK112, AK 112, AK-112, SMT112, SMT-112, SMT 112
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Akesobio, Summit Therapeutics
Drug class:
PD1 inhibitor, VEGF inhibitor
Related drugs:
‹
pembrolizumab (727)
nivolumab (607)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (43)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab-kcqx (7)
serplulimab (7)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
iparomlimab/tuvonralimab (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
ABP 206 (nivolumab biosimilar) (0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
finotonlimab (0)
BA1104 (nivolumab biosimilar) (0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BSI-585 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MK-3475 SC (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
nivolumab and hyaluronidase-nvhy (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
Pembroria (pembrolizumab biosimilar) (0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
ZG005 (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
recombinant human endostatin (5)
BI 836880 (0)
autologous activated lymphocytes (0)
TAVO412 (0)
ZGGS18 (0)
PTC299 (0)
STAR-LLD SC (0)
CU06 (0)
ABT-510 (0)
pembrolizumab (727)
nivolumab (607)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (43)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab-kcqx (7)
serplulimab (7)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
iparomlimab/tuvonralimab (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
(0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
finotonlimab (0)
(0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BSI-585 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MK-3475 SC (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
nivolumab and hyaluronidase-nvhy (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
(0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
ZG005 (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
recombinant human endostatin (5)
BI 836880 (0)
autologous activated lymphocytes (0)
TAVO412 (0)
ZGGS18 (0)
PTC299 (0)
STAR-LLD SC (0)
CU06 (0)
ABT-510 (0)
›
Associations
(3)
News
Trials
Filter by
Latest
4d
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=120, Not yet recruiting, West China Hospital
4 days ago
New P2 trial • Checkpoint inhibition
|
Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)
6d
Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
6 days ago
New trial
|
Yidafan (ivonescimab)
6d
Ivonescimab combined with chemotherapy treated with recurrent/persistent ovarian, fallopian tube, or primary peritoneal clear cell carcinoma patients:a single arm, open-label , single center exploratory study (ChiCTR2600115984)
P=N/A, N=20, Not yet recruiting, West China Second Hospital of Sichuan University; West China Second Hospital of Sichuan University
6 days ago
New trial
|
carboplatin • gemcitabine • albumin-bound paclitaxel • Yidafan (ivonescimab)
6d
Prospective, Single-Center, Single-Arm Clinical Study of Ivosidenib (AK112) Combined with Chemotherapy for Neoadjuvant Treatment of Locally Advanced Oral Squamous Cell Carcinoma (ChiCTR2600117076)
P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
6 days ago
New P4 trial
|
carboplatin • paclitaxel • docetaxel • pemetrexed • Tibsovo (ivosidenib) • Yidafan (ivonescimab)
6d
AK112 (Ivosimlimab) in combination with chemotherapy as first-line treatment for recurrent or advanced endometrial cancer (ChiCTR2500111544)
P4, N=50, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
6 days ago
New P4 trial
|
Yidafan (ivonescimab)
6d
A Study of Ivonescimab Plus Neoadjuvant Chemotherapy Followed by Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer (ChiCTR2600115927)
P2, N=42, Not yet recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
6 days ago
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • paclitaxel • Yidafan (ivonescimab)
6d
A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ChiCTR2600117652)
P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
6 days ago
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
Halaven (eribulin mesylate) • Yidafan (ivonescimab)
9d
Huaxi: Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
P2, N=154, Not yet recruiting, Sichuan University
9 days ago
New P2 trial
|
oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Yidafan (ivonescimab)
10d
PrE0510: Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=60, Recruiting, PrECOG, LLC. | Not yet recruiting --> Recruiting
10 days ago
Enrollment open
|
carboplatin • etoposide IV • Yidafan (ivonescimab)
14d
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, City of Hope Medical Center
14 days ago
New P1 trial
|
CD4 (CD4 Molecule)
|
irinotecan • leucovorin calcium • Yidafan (ivonescimab) • fluorouracil topical • muzastotug (ADG126)
15d
COLIBRI-GI: Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases (clinicaltrials.gov)
P2, N=130, Not yet recruiting, UNICANCER
15 days ago
New P2 trial • Mismatch repair • pMMR
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
15d
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (clinicaltrials.gov)
P=N/A, N=200, Not yet recruiting, Peking University People's Hospital
15 days ago
New trial
|
Yidafan (ivonescimab)
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.